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ABSTRACT 
Introduction  
Medication non-adherence can have a significant negative impact on treatment effectiveness. 
Standard intention-to-treat analyses conducted alongside clinical trials do not make 
adjustments for non-adherence. Several methods have been developed that attempt to estimate 
what treatment effectiveness would have been in the absence of non-adherence.  However, 
health technology assessment (HTA) needs to consider effectiveness under real-world 
conditions, where non-adherence levels typically differ from those observed in trials.  With this 
analytical requirement in mind, we conducted a review to identify methods for adjusting 
estimates of treatment effectiveness in the presence of patient non-adherence in order to assess 
their suitability for use in HTA.    
Methods 
A Ǯ
ǯ technique, with citation searching and reference checking  
was applied across seven electronic databases to identify methodological papers for adjusting 
time-to-event outcomes for non-adherence using individual patient data. A narrative synthesis 
of identified methods was conducted. Methods were assessed in terms of their ability to re-
estimate effectiveness based on alternative, sub-optimal, adherence levels. 
Results 
Twenty relevant methodological papers covering 12 methods and 8 extensions to those 
methods were identified. Methods are broadly classified into four groups: (1) simple methods, 
(2) principal stratification methods, (3) generalised methods (g-methods), and (4) 
pharmacometrics-based methods using pharmacokinetics and pharmacodynamics (PKPD) 
analysis. Each method makes specific assumptions and has associated limitations. Five of the 12 
methods are capable of adjusting for real-world non-adherence, with only g-methods and PKPD 
considered appropriate for HTA.  
Conclusion 
A range of statistical methods is available for adjusting estimates of treatment effectiveness for 
non-adherence, but most are not suitable for use in HTA. G-methods and PKPD appear to be 
more appropriate to estimate effectiveness in the presence of real-world adherence.  
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INTRODUCTION  
Patient non-adherence to medications can have a significant negative impact on treatment 
effectiveness and health care costs, and has the potential to alter the conclusions of economic 
evaluations and health technology assessments (HTA).1-3 An economic evaluation typically 
assesses the cost-effectiveness of a new treatment compared to standard treatment using 
evidence on clinical effectiveness and costs. Intention-to-treat (ITT) analysis, which compares 
randomised groups regardless of non-adherence or withdrawal, is a well-established method 
for estimating treatment effectiveness from randomised controlled trials (RCTs).4 However, ITT 
estimates may not be relevant if the HTA aims to assess the effectiveness of treatment given 
real-world adherence patterns.5,6  
There is evidence to show that adherence in the real world is likely to differ from RCTs 
(depending on the type of treatment, disease area, and health care setting) which leads to 
uncertainty around the actual effectiveness of treatments.7-9 Clinical effectiveness estimates 
have a direct impact on cost-effectiveness; consequently, a cost-effectiveness analysis (CEA) 
which does not incorporate non-adherence may produce misleading conclusions regarding the 
value of the technology. In the HTA context, we are interested in effectiveness estimates 
inferred to the entire study population (as defined by scope and study eligibility criteria) which 
can be identified at baseline, as opposed to estimates focused on a latent subgroup of the 
population (e.g. compliers).  Moreover, HTA agencies are interested in adjustment methods 
which can be used for re-estimating treatment effectiveness for any given level of adherence, in 
order to reflect potential real-world adherence levels.10,11 
The fundamental issue in estimating effectiveness associated with alternative adherence levels 
is the methodological challenge associated with adjusting for time-dependent confounding. In 
this context, time-dependent confounders are prognostic factors which predict subsequent non-
adherence and outcomes, yet are themselves predicted by previous non-adherence.12 When 
time-dependent confounders are present, more complex methods than simple regression 
adjustment are needed because simple regression adjustment is unable to deal with variables 
that predict adherence and are also an intermediate step between adherence and outcome. A 
range of methods have been proposed for estimating the causal effect of treatments in the 
presence of non-adherence, however, little guidance exists about their relative advantages,13-15 
and not all deal with time-dependent confounding appropriately. In addition, these methods 
have been designed, principally, to re-estimate effectiveness assuming perfect adherence, 
whereas HTA requires re-estimation for sub-optimal (real world) adherence. 
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The aims of the review are to systematically identify approaches for adjusting for non-
adherence in the context of time-to-event outcomes using individual patient data in RCTs, to 
describe how each is undertaken and to assess their suitability for re-estimating effectiveness 
based on alternative, sub-optimal, adherence levels. 
METHODS 
Review Question and Protocol 
The review question was: ǲ
account for the impact of non-adherence to treatments on clinical effectiveness and cost-
ǫǳThe review approach adheres to published international guidelines for 
undertaking and reporting systematic reviews and methods were pre-specified in a protocol.16-
20  
Search Strategy 
A ǲComprehensive Pearl Growingǳ (CPG) technique17 and two-stage iterative search approach 
was used across seven databases (Medline, Embase, Cochrane Library, EconLit, Scopus, Web of 
Science, MathSciNet). Databases were searched for potentially relevant papers published in 
English from inception to 9th February 2018 (first stage search) to 23rd May 2018 (second stage 
search). The database searches were complemented by citation searches and reference list ǮǯȋȌǤ The search approach 
was designed to identify the initial paper proposing the method (or articles reporting 
extensions to a previously developed method), rather than articles reporting the application of 
methods in studies.   
The database search strategy comprises keywords for patient adherence combined with 
methods terms and focused MeSH headings of known pearls. The second iteration search was 
informed from the collective analysis of newly identified pearls title, abstract, keywords, MeSH 
and floating headings using the online Yale MeSH Analyzer Tool.13,21-28 Search terms and 
strategies are provided in Appendix A.  
Inclusion and Exclusion Criteria 
The selection of papers included for narrative synthesis was conducted in two stages: (1) 
records retrieved from all sources were screened by titles followed by abstracts screening; and 
(2) potentially relevant full-text articles were assessed for eligibility using the inclusion and 
exclusion criteria (Table S1). One author (A.A.) screened all potentially relevant papers 
retrieved. A second author (S.D.) independently screened a subset of papers against the 
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eligibility criteria. Disagreements between the two reviewers were resolved by discussion and a 
consensus was reached on the final list of included papers. Expert opinion was obtained from 
two experts (D.H., I.W.) for recommendation of additional papers. 
Data Extraction 
A data extraction form was developed to extract the basic information and key characteristics 
for each method identified (Table S2).  
Data Synthesis  
A narrative data synthesis approach was followed for each relevant method identified and their 
extensions. This included a description of the key characteristics of each method, as specified by 
the appraisal framework (Table S3).29 As part of this, we assessed which forms of non-
adherence the method is capable of addressing, using the classification developed by Vrijens 
and colleagues.28 This classification differentiates between three stages of medication non-
adherence:  (1) initiation (when the first dose is taken by the patient); (2) implementation (how 
closely the actual dosage of a patient corresponds to the prescribed dosing regimen); and (3) 
persistence (time to discontinuation or end of therapy).28  
We provide a brief description of the concept of each adjustment method, together with the 
causal model, its estimand (defined in the next section), key assumptions and limitations. We 
assess whether the method is capable of re-estimating effectiveness for other sub-optimal levels 
of adherence (as opposed to optimal adherence). This assessment was based on the capability of 
the method to estimate the treatment effect under alternative counterfactual adherence levels 
(i.e. not observed adherence levels) given the adherence level and treatment effect actually 
observed in the trial. Finally, we assess the appropriateness of non-adherence adjustment 
methods for the HTA context based on criteria developed by the authors. The criteria were: (1) 
the suitability of the estimand (as described in the next section), (2) the types of non-adherence 
the method is capable of dealing with, and (3) whether it is possible to use the method to 
account for real-world non-adherence levels.  
Possible Estimands and Suitability for HTA 
An estimand is the parameter of interest estimated by the statistical method that we can use to 
make inferences about a population using a sample from that population.5,30 A range of possible 
estimands was identified, however, only a few are appropriate for HTA. In the HTA context, 
resource allocation decisions are usually made for a specified population defined by the scope 
for each decision problem. Hence, the estimands of interest are those covering the entire study 
population (as specified by the RCT eligibility criteria) and this should be identifiable at baseline 
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for resource allocation decision making. Therefore, estimands focused on latent subgroups of 
patients (e.g. compliers) may not be appropriate for the HTA context. 
RESULTS 
Overview of Included Papers 
This review includes 20 papers describing 12 methods and 8 extensions to those methods.22,31-49 
In total, the searches resulted in 4472 records (Figure 1). The included papers were published 
between 1992 and 2018 (inclusive), the majority were published in the Statistics in Medicine 
journal (30%) and Biometrics journal (25%). Other characteristics of included papers are given 
in Table S4. 
Taxonomy of Methods 
A taxonomy of methods for adjusting estimates of treatment effectiveness for non-adherence in 
the context of time-to-event outcomes is proposed (Table 1). The purpose of the taxonomy is to 
increase understanding of the concept behind each method and its relation to other methods in 
terms of estimands and estimators.30 The structure of the taxonomy was initially developed by 
one author (A.A.) and further revised based on consultations with other authors (N.L., P.T., D.H., 
J.F, S.D.) and an expert in causal inference methods (I.W.).  
In the proposed taxonomy, methods are broadly classed into four groups: (1) simple methods 
which do not appropriately adjust for non-adherence; (2) principal stratification methods for 
estimating the Complier Average Causal Effect [CACE] estimand;50 (3) generalised methods (g-
methods) which are based on the counterfactual outcome framework originally developed by 
Neyman51 and Rubin52 for estimating the effect of time-fixed treatments, and further extended 
by Robins53,54 for time-varying treatments; and (4) pharmacometric-based methods as a unique 
approach using pharmacokinetics and pharmacodynamics (PKPD) analysis commonly used in 
clinical trials for evaluating newly developed pharmacological interventions. The estimand and 
key assumptions used by each method are provided in Table 2, and the appropriateness for HTA 
is provided in Table 3. We provide an overview of methods in each group in the following 
subsections. We do not further describe the ITT analysis, since it does not attempt to adjust for 
non-adherence. 
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Simple methods 
Per-Protocol (PP) Analysis 
The standard PP analysis strategy attempts to estimate the treatment effect among adherent 
patients by excluding protocol non-compliers.45 PP can deal with random (non-selective) types 
of non-adherence (initiation, implementation, persistence). The main concern is that excluding 
some patients from the analysis may undermine the prognostic balance generated by the 
randomisation which may introduce selection bias. This is likely to be the case if non-adherence 
is not random, i.e. if non-adherence is influenced by other patient characteristics and prognostic 
factors.55 Even if prognostic factors which are associated with non-adherence are correctly 
identified, PP analysis will introduce bias in the presence of time-dependent confounding.  
As-Treated (AT) Analysis 
The AT method attempts to adjust for the random initiation type of non-adherence. AT 
estimates the Average Causal Effect (ACE) among patients who actually received the treatment 
compared to those who did not receive the treatment, assuming they are similar regardless of 
randomisation.34 The main problem with this approach is that the group who actually received 
the treatment is unlikely to be comparable to the group who did not, making this approach 
prone to selection bias.56 AT analysis is less commonly used in practice compared with ITT and 
PP conventional methods.  
Principal Stratification Methods 
Cox Proportional Hazards Model with Partial-Likelihood Estimator (PLE) 
The CPH model with PLE is a method for estimating the treatment effect adjusted for initiation 
non-adherence at baseline while respecting the randomisation.41 This is a semi-parametric 
model whereby the treatment effect on the distributions of failure times is the parametric part. 
In the basic model, an individual with covariates (k, z0, z) will have a hazard function presented 
in equation [1].   ሺߛ்ݖ଴ ൅ ߚݖ ൅ ߛ௞ሻ ߣሺݐሻሾ ?ሿ 
where ߛ் is the treatment effect in compliers (CACE estimand) expressed in terms of the hazard 
at time ݐ for a cumulative hazard function Ȧk(t) (this is only observable for the compliers class), ߛ௞ is the adherence class of the kth individual, ݖ଴ is a vector of baseline covariates, and z is a set 
of time-dependent covariates. The standard method assumes that covariates are independent of 
non-adherence. The method can be used to adjust for non-adherence in situations where non-
adherence is dependent on baseline covariates, but this approach requires a more complex 
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estimator.41 The key limitation of this method is the difficulty of modelling time-varying 
treatments and other types of non-adherence beyond initiation.  
Markov Compliance Class (MCC) Model in a 3-Stage Method 
The MCC model can accommodate both initiation and time-varying non-adherence 
(implementation) in the context of longitudinal studies where patients are randomised at 
baseline and randomisation is maintained over time.42 The concept of this method is based on 
specifying two possible adherence classes which are applied at specified time points, e.g. five 
time points results in a total of 32 (25) adherence patterns. A stratification strategy can then be 
used to stratify adherence patterns into super-classes (low compliers, decreasing compliers and 
high compliers). This can be used to estimate the CACE estimand among the compliers 
superclass. Model [2] can then be used to account for the relationship between adherence and 
survival time at time t. ݄ሺݐȁ ௜ܷ ൌ ݇ሻ ൌ ݄଴ሺݐሻ ൫ߚ௞ܫሺ ௜ܷ ൌ ݇ሻ൯ሾ ?ሿ   
where ߚ௞ for one of the adherence superclasses is assumed 0 for identification (reference 
superclass) and  ௜ܷ  is individual iǯ݇ number of superclasses.42 As a 
limitation, the method cannot deal with time-dependent confounding. 
Weighted Per-Protocol (Wtd PP) Analysis with Expectation-Maximisation Estimator 
The Wtd PP method estimates the CACE by focusing on the ambivalent (compliers) class. The 
method attempts to deal with treatment initiation over time with two main features: (1) 
proposing a Wtd PP estimator by using time-varying weights which are subject-specific (depend 
on baseline and time-dependent covariates) in a survival model; and (2) proposing an 
expectation-maximisation algorithm to maximise the full-likelihood (FL) and PLEs.47 The 
method was developed to adjust for time-dependent confounders which are associated with 
non-adherence. The partial-likelihood estimator used by this model is similar to that used in the 
CPH with PLE approach (model [1]). Details of the FL estimator are reported in Li and Gray.47       
Compliers PROPortional Hazards Effect of Treatment (C-PROPHET) 
The C-PROPHET identifies adherent patients (initiation at baseline) and estimates the treatment 
effect in this group, adjusting for baseline covariates.39 C-PROPHET is a semi-parametric model 
with the parametric side being the effect of the exposure on the survival times distribution.39  If 
individual patients who actually adhered to the protocol can be predicted at baseline in the 
intervention and control arms of an RCT, then one could fit a PH model for this study 
subpopulation to estimate the treatment effect. 
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The C-PROPHET model assumes that the hazard of survival time (Ti) is as provided in equation 
[3]. 39 ߣሺݐȁܼ௜ ൌ  ?ǡ ܧଵ௜ ൌ  ?ሻ ൌ ߣሺݐȁܼ௜ ൌ  ?ǡ ܧଵ௜ ൌ  ?ሻሺ߰଴ሻሾ ?ሿ 
where Zi is the randomisation variable for individual i (ܼ௜ ൌ  ?  for the intervention group, ܼ௜ ൌ  ? 
for the control group) and ܧଵ௜ represents the principal stratum at the treatment initiation stage. 
The parameter ߰଴ denotes the causal proportional hazards effect in the subpopulation of 
compliers. This is the parameter of interest which is called C-PROPHET.39 In terms of 
limitations, the method cannot be used to adjust for time-dependent non-adherence. 
Instrumental Variable Method 
The IV method can be used for adjusting for all types of non-adherence using a binary 
adherence variable. The method relies on the exclusion restriction assumption; that is, the IV 
affects the survival outcome only through its effects on the exposure. Three variants of the IV 
approach were identified: (1) IV with Likelihood Estimator,32 (2) IV with Plug-in Non-
Parametric Empirical Maximum Likelihood Estimator (PNEMLE),43 and (3) Transformation 
promotion time cure model with MLE.48  
The IV with Likelihood estimator works by classifying individuals in the trial population into four 
groups (similar to the classification used by MCC method). The estimator should be used to 
calculate the probability of having the case-specific event of interest at time t for each latent 
adherence class. Treatment effect in terms of HR can then be computed. This method was further 
applied to estimate adherence-adjusted cost-effectiveness using RCT data.32  
The PNEMLE approach assumes the following survival functions for compliers in the 
intervention group (equation [4]) denoted as Sc1(V) and control group (equation [5]) denoted as 
Sc0(V), while never-takers have similar survival function in both groups denoted as Snt(V).   ்ܵȁܴ ൌ  ?ሺܸሻ ൌ ߨ௖ܵ௖ଵሺܸሻ ൅ ሺ ? െ ߨ௖ሻܵ௡௧ሺܸሻሾ ?ሿ ்ܵȁܴ ൌ  ?ሺܸሻ ൌ ߨ௖ܵ௖଴ሺܸሻ ൅ ሺ ? െ ߨ௖ሻܵ௡௧ሺܸሻሾ ?ሿ 
wɎc is the fraction of compliers in the intervention group.  
The IV extension using transformation promotion time cure model is a semi-parametric model 
for estimating CACE and CESP (Complier Effect on Survival Probability) estimands. Further 
details of this extension are reported in Gao and Zheng.48  By using an IV approach, the analyst 
can deal with time-dependent confounding. The main drawback of this method is finding an 
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instrumental variable that meets all the criteria of a valid IV;15 an inadequate IV can lead to an 
imprecise and/or biased estimate.  
G-methods 
Marginal Structural Models (MSMs) with Inverse Probability of Censoring Weighting 
(IPCW) / Inverse Probability of Treatment Weighting (IPTW) 
This method can be used to adjust for all types of non-adherence by censoring individuals at the 
first time they become non-adherent and then use IPCW for estimating the ACE of treatment 
using MSMs.22 The IPCW can be used to obtain a valid treatment effect by adjusting for baseline 
and time-dependent confounders. IPCW makes the ǲno unmeasured confoundingǳ assumption; 
that is, the assumption of explainable non-random non-adherence by measured time-dependent 
confounders.13,22 Stabilised weights are used because unstablised weights can be inefficient. In 
practice, the analyst should construct stabilised weights (ݓෝ௜௧௦௧௔௕ሻ for each individual i in time 
interval t by multiplying all the probabilities of remaining uncensored (adherent) up to time t 
using equation [6]. ݓෝ௜௧௦௧௔௕ ൌ  ? ଵଵି௣ො೔ೖ௧௞ୀ଴ Ȁ  ? ଵଵି௣ොబ೔ೖ௧௞ୀ଴ ൌ   ? ଵି௣ොబ೔ೖଵି௣ො೔ೖ௧௞ୀ଴ ሾ ?ሿ      
where ݌Ƹ௜௞  is the predicted probability of non-adherence in time interval k given the 
randomisation group and adjusting for baseline and time-dependent covariates,  ݌Ƹ଴௜௞ is the 
probability of non-adherence given the randomisation group and adjusting for baseline 
covariates only. A pseudo-population should be created using the IPCW, and then any survival 
analysis (e.g. a Cox Partial-Likelihood Estimator) can be applied for estimating adherence-
adjusted effectiveness. The main limitation of IPCW is the assumption of no unmeasured 
confounders, which cannot be proven empirically.  
As an alternative approach to IPCW, one could allow individuals to become adherent again 
following a period of non-adherence - this can be modelled using the IPTW approach.35 The key 
feature of this method is that it allows for modelling longitudinal adherence patterns where 
patients follow erratic adherence behaviours in implementing the prescribed dosing regimen 
(i.e. on/off adherence patterns).     
Structural Nested Failure Time Models (SNFTMs) with G-estimation 
The SNFTM can be applied to adjust for all types of non-adherence by controlling for time-
dependent confounding using the G-estimation technique.31 The model ǯ
observed survival time and treatment history to the counterfactual outcome. In the SNFTM 
framework, the no unmeasured confounding assumption implies that the potential outcome 
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does not add to the prediction model for treatment initiation, conditional on other covariates 
included in the model. To formally explain the G-estimation procedure, let us assume the 
treatment effect model in equation [7].57 We fit a logistic regression model to obtain the 
coefficients in equation [8].  ܻ௧  ? టܺሺݐሻ݃݅ݒ݁݊൫ܣ௧ ǡ ܮ௧൯ሾ ?ሿ ܲሾܣሺݐሻሿ  ൌ ߚ଴ሺݐሻ ൅ ߚଵܣሺݐ െ  ?ሻ ൅ ߚଶܮሺݐሻ ൅ ߚଷܺ߰ሾ ?ሿ 
where ܻ௧ is the observed survival time,  ?means has the same distribution as,  ܺటሺݐሻ is the 
counterfactual outcome, ܣ௧ is the past treatment, ܮ௧is the history of covariates andܲሾܣሺݐሻሿ is 
the probability of initiating the treatment at time t.  
G-estimation is used to search for ߰ value which adds the least to the prediction model (i.e. 
treatment initiation is independent of counterfactual outcomes). This means we search for a 
value of ෠߰ that results in aܺ߰ term having a coefficient  ߚଷ ൌ zero in model [8]. That value of ߰ 
provides the best estimates of counterfactual survival times adjusted for non-adherence. The 
main limitation of SNFTMs is the potential biases related to the no unmeasured confounding 
assumption, which cannot be formally tested. 
Rank-Preserving Structural Failure Time Models (RPSFTMs) with G-estimation 
The RPSFTM is a semi-parametric model for adjusting for initiation non-adherence using the 
randomisation factor, observed survival time and treatment history.36 The method relies on the ǲcommon treatment effectǳ assumption (equal treatment effect regardless of when the 
treatment was initiated, but relative to the time for which the treatment was received). It also 
relies upon the randomisation of the trial meaning that counterfactual survival times are equal 
between groups.  
A simple RPSFTM (equation 9) can be constructed to estimate the counterfactual survival time 
( ௜ܶ଴).14,38 
௜ܶ଴ ൌ න ሾെܼ߰௜ܣ௜ሺݐ்೔଴ ሻሿ݀ݐሾ ?ሿ 
whereܼ௜  is the randomisation variable, ܣ௜  is a binary adherence variable which equals 1 when a 
patient initiated the treatment and 0 otherwise, ௜ܶis the observed survival time and the factor ሺ߰ሻis the causal effect (the value by which survival time is shrunk or expanded as an effect 
of thȌǤǲǳ ߰ (which we can find using G-
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estimation), the counterfactual survival between randomised groups will be equal and that 
value of ߰ would be the point estimate of the treatment effect.  
RPSFTM allows us to deal with time-dependent initiation issues and can deal with time-
dependent confounding. The original RPSFTM was extended to incorporate baseline covariates 
to improve the precision of estimators,37, 38 and uses re-censoring to allow the method to deal 
with potentially informative censoring in the counterfactual dataset.33,40 As limitations, the 
RPSFTM can only be used for adjusting for the initiation type of non-adherence and it relies on 
the common treatment effect assumption, which is difficult to test.  
Pharmacometrics-based Methods 
Pharmacokinetics and Pharmacodynamics (PKPD) Based Method 
The PKPD based methods model all types of non-adherence for estimating treatment 
effectiveness. PKPD-based methods require model development and fitting using appropriate 
data, typically collected during each phase of clinical drug development; and simulation based 
on different patterns of adherence, dosing schedules, and patient characteristics where 
covariate effects are relevant. The pharmacodynamic endpoint may be of direct relevance 
(e.g. anticoagulant international normalised ratio (INR)) or may require extrapolation, to 
estimate the link between the PKPD parameter and the outcome of interest (e.g. risk of 
cardiovascular events) using evidence from the literature.44,58 PKPD makes the exclusion 
restriction assumption, that is, randomisation affects the outcome only through the exposure 
treatment.  
The PKPD method has been extended for modelling varying non-adherence and estimating 
adherence-adjusted cost-effectiveness of treatments.44,49 The main limitations of this method is 
its reliance on an accurate model specification and PKPD data which might not be routinely 
available in RCTs or observational studies across disease areas. 
Appropriateness of Non-Adherence Adjustment Methods to the HTA Context  
The results based on the criteria applied for assessing appropriateness (suitability of the 
estimand, type of non-adherence and possibility to account for real-world non-adherence 
levels) for each of the identified adjustment methods is provided in Table 3. Five methods (ITT, 
MSMs, SNFTMs, RPSFTMs and PKPD) generate the estimand that is appropriate for HTA 
(covering the entire study population), with only three of these being capable of accounting for 
all types of non-adherence (MSMs, SNFTMs and PKPD). Five methods are thought to be capable 
of re-estimating effectiveness for real-world levels of non-adherence. When looking across all 
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three facets of estimating effectiveness for HTA, g-methods and PKPD appear to be more 
appropriate. 
The main differences between the four classes of methods are the estimands, assumptions, and 
the types of non-adherence that each method is capable of dealing with. Simple methods are 
only valid in the presence of random (non-selective) non-adherence. Principal stratification 
methods are capable of adjusting for some types of non-adherence, but their estimands seem 
inappropriate for HTA context based on the criteria we set out in the methods section. Both g-
methods and PKPD can deal with real-world non-adherence and their estimands are 
appropriate for HTA. G-methods are similar in terms of their capability for adjusting 
effectiveness estimates for counterfactual non-adherence levels. However, PKPD is a unique 
method that uses a different approach compared to g-methods.  
In practice, the analyst could apply g-methods to individual patient-level data from an RCT to 
re-estimate treatment effectiveness (adjusted for non-adherence) for populating cost-
effectiveness models. Real-world adherence levels could be estimated from registry data or 
observational studies. All g-methods could be applied using standard software (e.g. SAS, Stata or 
R).12,59-61 While g-methods could be applied to real RCT datasets, the PKPD approach relies on 
simulating an RCT dataset based on a specified pattern of non-adherence (e.g. real world 
adherence), and then uses the simulated data for generating the adjusted estimates. This would 
require data (including PKPD data) collected at different phases of clinical drug development. 
PKPD method can be applied using a specialist software (e.g. NONMEM) or standard software 
(e.g. R) for simulating the dataset.62   
DISCUSSION 
A total of 12 methods for adjusting for non-adherence in the context of time-to-event outcomes 
were identified and briefly described in this article. The proposed taxonomy classifies 
adjustment methods into four groups: (i) simple methods, (ii) principal stratification methods, 
(iii) g-methods, and (iv) pharmacometrics-based methods. Each method makes specific 
assumptions and has associated limitations, and many of these assumptions are non-testable. 
Identification and collection of baseline and time-dependent confounders were identified as 
crucial for adjusting for non-adherence.  
The purpose of adjustment was highlighted as a fundamentally important issue as estimands 
differ between the methods, as do the practicalities of using the method to re-estimate 
effectiveness for alternative levels of adherence. G-methods and PKPD appear more appropriate 
for adjusting effectiveness estimates given real-world adherence levels and the likely existence 
14 
 
of time-dependent confounding in RCT datasets. Simple methods and principal stratification 
methods cannot re-estimate effectiveness based on alternative, sub-optimal, adherence levels. 
Wtd PP method uses weights similar to IPCW, but the estimand is restricted to the compliers 
subpopulation. 
Many potentially relevant papers with a focus on cost-effectiveness aspects were excluded as 
these did not provide a methodological contribution. This gap in the methodological literature 
on CEA for modelling the link between non-adherence and treatment effectiveness is consistent 
with findings from other studies.8,63 A previous review by Hughes et al.27 reported five methods 
for adjusting cost-effectiveness for non-adherence which was focused on pharmacoeconomic 
models rather than the impact of non-adherence on effectiveness. In that review, the PKPD 
approach is the only method relevant to our review with the other methods being health-
economic models (Decision tree, Markov, Discrete-event simulation) for incorporating 
adherence-adjusted treatment effects in economic evaluations.  
Many of the methods identified by our review have been described and compared (mostly in 
pairwise comparisons) in the methodological literature.13,14,34,64,65 Mostazir et. al. published a 
review of methods for handling non-adherence to intervention protocols in RCTs which 
identified some of the methods; however, their review missed several relevant methods due to 
the restricted search strategy used.66 The limitations of simple methods in adjusting for non-
adherence is consistently reported in the methodological literature.33,34,39,45,56,64,67 It has been 
noted previously that principal stratification methods require a binary adherence variable (e.g. 
compliers/non-compliers) which may be problematic as a threshold is required and this is often 
arbitrarily decided (e.g. 80% adherence level).68 This may also be an issue for g-methods and 
PKPD methods, where, in adjusting for non-adherence, we first need to define what constitutes ǲǳǤ-adherence adjustment methods are likely to 
be useful in an HTA context. However, the remaining methods all have limitations and their 
performance in relevant scenarios is unknown.  
This review has used novel iterative search techniques and followed international guidelines,16-
18 but has limitations. First, a higher number of papers were excluded at the title screening stage 
because the ǯas not relevant. Second, we excluded non-peer reviewed reports and 
other grey literature. While these two limitations might be an issue, the final list of included 
papers was checked by two experts, and we are confident that no important relevant method 
was missed. Third, minor variants of methods extensions are not included (e.g. proposing 
alternative censoring mechanisms for IPCW)69, which is inevitably a subjective decision. These 
decisions were based on discussions amongst the authors. Finally, the review does not assess 
the performance of the alternative methods; therefore, further research (well-conducted 
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simulation studies) is warranted to provide recommendations for application in the HTA 
context.  
In conclusion, economic evaluations frequently ignore the adjustment of treatment effectiveness 
for patient non-adherence which carries the risk of producing misleading cost-effectiveness 
evidence if adherence levels in the real world differ from trials. A range of statistical methods 
are available for adjusting estimates of treatment effectiveness in the presence of patient non-
adherence, although g-methods and PKPD appear to be more promising to account for real-
world adherence levels in HTA.  Further research is warranted to assess the performance of 
these methods.  
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TABLES 
Table 1 Taxonomy of Methods for Adjusting Treatment Effectiveness for Non-adherence in the 
Context of Time-to-event Outcomes  
Methods group Method sub-
category 
 
Method/Extension Reference    
Simple methods ITT * Intention-To-Treat (ITT) analysis Yu et al., 201546 
PP Per-Protocol (PP) analysis 
 
Wu et al., 201545 
AT As-Treated (AT) analysis Korhonen et al., 199934 
Principal 
stratification 
methods  
CPH with PLE Cox Proportional Hazards (CPH) 
Model with Partial likelihood 
Estimator (PLE) 
Cuzick et al., 200741 
MCC Markov Compliance Class (MCC) 
Model in a Three-Stage Method (3SM) 
Lin et al., 200742 
Wtd PP Weighted Per-Protocol (Wtd PP) 
analysis using a Proportional Hazards 
Model with an Expectation-
Maximisation (EM) Estimator  
Li and Gray, 201647 
C-PROPHET Compliers PROPortional Hazards 
Effect of Treatment (C-PROPHET) 
Loeys and 
Goetghebeur, 200339 
IV Instrumental variable (IV) with 
Likelihood Estimator 
Baker, 199832 
 
IV with Plug-in Non-Parametric 
Empirical Maximum Likelihood 
Estimation (PNEMLE)  
Nie et al., 201143 
 
Transformation Promotion Time Cure 
Model with MLE to estimate the 
Compliers Average Causal Effect 
(CACE) and the Compliers Effect on 
Survival Probability (CESP) 
Gao and Zheng, 201748 
 
G-methods MSMs  Marginal Structural Models (MSMs) 
with Inverse Probability of Censoring 
Weighting (IPCW) 
Robins and 
Finkelstein, 200022 
 
MSM Extension: MSMs with Inverse 
Probability of Treatment Weighting 
(IPTW) 
Hernan et al., 200135 
SNFTMs Structural Nested Failure Time 
Models (SNFTMs) with G-estimation 
Robins et al., 199231 
RPSFTMs 
 
Rank-Preserving Structural Failure 
Time Models (RPSFTMs) with G-
estimation 
Loeys et al., 200136 
 
RPSFTM Extension: Incorporating 
covariates to improve the precision of 
estimators  
Korhonen and 
Palmgren, 200237 
22 
 
RPSFTM Extension: Improving the 
efficiency of the estimators  
Loeys and 
Goetghebeur, 200238 
 
RPSFTM Extension: Allowing for 
dependent censoring 
Matsui, 200440 
 
RPSFTM Extension: Choice of model 
and impact of recensoring 
White and 
Goetghebeur, 199833 
Pharmacometrics-
based methods  
PKPD Pharmacokinetics and 
Pharmacodynamics (PKPD) based 
method 
Pink et al., 201444 
 
PKPD Extension: Modelling varying 
implementation and persistence types 
of non-adherence  
Hill-McManus et al. 
201849 
* ITT does not adjust for non-ǡǲǳ
(i.e. ignoring non-adherence)   
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Table 2 Estimands, Causal Interpretation of Estimates and Key Assumptions for Non-Adherence 
Adjustment Methods  
Method Estimand* Estimand Attribues  Causal Interpretation of the 
Estimate  
Key Assumptions    
ITT 
 
The effect of 
treatment 
assignment 
(not the 
effect of 
treatment 
itself) 
Entire study 
population; ignoring 
events such as non-
adherence and 
dropout 
The average causal effect of 
treatment assignment on the survival 
outcome in a particular study 
(regardless of adherence, dropout, ǥȌ 
The randomisation 
assumption (i.e. group 
membership is randomly 
assigned), which implies 
that groups are 
comparable or 
exchangeable.  
PP 
 
The effect of 
following the 
study 
protocol  
Subpopulation of the 
protocol compliers in 
the study; excluding 
protocol non compliers 
from the analysis set 
The average causal effect of 
treatment on the survival outcome in 
individuals who adhered to the 
protocol in terms of eligibility, 
adherence, outcome assessment, etc...  
The groups of patients 
who adhered to the 
protocol in each arm are 
comparable after 
covariate adjustment.  
AT The effect of 
treatment 
actually 
received  
Subpopulation of 
patients who initiated 
treatment; with 
patients who switched 
treatment analysed 
with the group they 
switched to regardless 
of randomisation  
The average causal effect of 
treatment on the survival outcome 
among individuals who actually 
received the treatment in the 
experimental group (including 
control group patients who switched 
on to the experimental treatment) 
compared to those who actually 
received the standard treatment (or 
those actually not received the 
treatment in placebo-controlled 
trials) regardless of treatment 
assignment  
The group of patients 
who received the 
treatment is comparable 
to those who did not, 
regardless of their 
treatment assignment. 
CPH 
with 
PLE 
The complier 
average 
causal effect 
(CACE) 
Subpopulation who 
adhered to the 
protocol; excluding 
patients who did not 
adhere to the protocol 
in each arm of the 
study  
The average treatment effect on the 
survival outcome in the compliers 
subpopulation (patients who 
adhered to the protocol)  
Covariates included in 
the model are 
independent of 
adherence 
MCC CACE As above As above - The Markov 
assumption  
- Time-varying 
adherence depends on 
the history of 
adherence  
- Latent and ignorable 
missing data 
mechanism 
Wtd PP  CACE As above As above Patient population 
consists of three 
(possibly latent) ǣǮǯǡ
Ǯǯand Ǯrefusersǯ 
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C-
PROPH
ET 
CACE As above As above  The exclusion restriction 
assumption 
IV CACE As above As above 
 
 
- The exclusion 
restriction assumption 
- Randomisation has no 
effect on the 
probability of 
adherence to treatment 
- Monotonicity 
assumption  
MSMs 
with 
IPCW/I
PTW 
The effect of 
treatment 
had 
everyone 
remained 
adhered to 
the protocol  
 
 
 
 
 
 
Entire study 
population; had 
everybody adhered to 
the protocol with 
perfect adherence to 
the prescribed dosing 
regimen (or had 
everybody adhered to 
the protocol at an 
alternative level of 
adherence to the 
prescribed dosing 
regimen than what 
was observed in the 
trial(e.g. real-world 
adherence level)  
The average causal effect of 
treatment that would have been 
observed if everybody adhered to the 
protcol. MSMs estimate the average 
treatment effect in the entire 
population, but the causal effect in a 
subset of the population (defined by 
a combination of variables L) can also 
be estimated. The IPCW estimand can 
also be interpreted as a comparison 
of the potential (counterfactual) 
outcomes under different levels of 
adherence in the same group of 
subjects.      
- No unmeasured 
confounders  
- Positivity assumption  
SNFTMs 
with G-
estimati
on 
The effect of 
treatment 
had 
everyone 
remained 
adhered to 
the protocol  
 
As above The average treatment effect that 
would have been observed if 
everybody adhered to the protocol 
(or remained at a particular 
adherence level such as real-world 
adherence level). SNFTMs can be 
used to estimate the average causal 
effect in a subset of the population 
defined by a combination of factors 
(L), e.g. men, patient aged >60 years, ǥ   
- No unmeasured 
confounders 
- Survival times and 
treatment-free survival 
times are proportional 
by an unknown factor 
that depends on the 
exposure 
RPSFT
Ms with 
G-
estimati
on 
The effect of 
treatment 
had 
everyone 
remained 
adhered to 
the protocol  
 
As above The average treatment effect that 
would have been observed if 
everybody adhered to the protocol 
compared to none treated.  
- The randomisation 
assumption 
- The common treatment 
effect assumption 
- Survival times and 
treatment-free survival 
times are proportional 
by an unknown factor 
that depends on the 
exposure 
PKPD 
method 
The effect of 
following a 
particular 
Entire study 
population; given a 
particular pattern of 
The average causal effect of 
treatment if individuals followed a 
particular adherence pattern. 
- The exclusion 
restriction assumption 
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adherence 
pattern in 
the study 
population 
adherence to the 
prescribed dosing 
regimen 
- Correctly specified 
model 
CACE=Complier Average Causal Effect; ITT=Intention-to-Treat; PP=Per-Protcol; AT=As Treated; CPH=Cox 
Proportional Hazards; PLE=Partial Likelihood Estimator; MCC=Markov Compliance Class; Wtd PP= Weighted Per-
Protocol; C-PROPHET= Complier PROPortional Hazards Effect of Treatment; IV=Instrumental Variable; 
MSMs=Marginal Structural Models; SNFTMs=Structural Nested Failiure Time Models; RPSFTMs= Rank-Preserving 
Stuctural FAiliure Time Models; PKPD=Pharmacokinetics and Pharmacodynamics. 
* The estimand is the parameter of interest defined using four attributes: (i) the population, (ii) the outcome variable 
or endpoint, (iii) the specification of how to deal with intercurrent events (e.g. include compliers only), and (iv) the 
population-level summary of the outcome variable. The description of the estimand in this table is focused on two 
attributes (the population and specification of how to deal with intercurrent events)) as the other two attributes (the 
outcome variable and the population-level summary of the outcome variable) are expected to be similar in the 
context of time-to-event outcomes.  
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Table 3 Appropriateness of estimand for the HTA context, types of non-adherence, possibility 
to account for real-world adherence levels and suitability of the effectiveness estimates for HTA 
using the alternative adjustment methods  
Method Appropriateness 
of estimand for 
the HTA context 
* 
Type of non-adherence which can 
be adjusted for using the method 
Possibility 
to account 
for real-
world non-
adherence 
levelsș 
Suitability 
of the 
method 
for use in 
HTA 
Notes 
Initiation, 
Implementation, 
Persistence 
Random, 
Explainable 
non-random, 
No-randomȘ 
ITT Yes None None No No - The estimand is 
marginalised to the 
entire population. 
- Cannot estimate 
counterfactual estimands 
(i.e. treatment 
effectiveness given 
adherence levels in the 
real world). 
PP No Initiation, 
implementation, 
persistence  
Random No No - The estimand is not 
marginalised to the 
entire population.  
- Excluding the protocol 
non-compliers may break 
the randomisation 
balance leading to 
selection bias if protocol 
non-compliance is 
related to underlying 
prognosis. 
AT No Initiation Random No No -  Does not respect the 
randomisation balance 
which may lead to 
selection bias. 
-  Cannot estimate 
counterfactual estimands 
CPH with 
PLE 
No Initiation Random, 
Explainable 
non-random 
No No - The CACE estimand 
used by all five methods 
is not marginalised to the 
entire population.  
- The compliers class is a 
latent group of patients 
which is not identifiable 
at baseline, making it 
difficult for policymakers 
to make resource 
allocation decisions 
based on CACE estimand. 
- IV can estimate 
effectiveness given real-
world adherence level 
based on the 
counterfactual outcome 
framework 
MCC No Initiation, 
Implementation 
Random No No 
Wtd PP No Initiation Explainable 
non-random 
No No 
C-PROPHET No Initiation Non-random No No 
IV No Initiation, 
Implementation, 
persistence 
Non-random Yes No 
MSMs Yes Initiation, 
implementation, 
persistence 
Explainable 
non-random 
Yes Yes - Effectiveness estimates 
are marginalised to 
entire study population. 
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SNFTMs Yes Initiation, 
implementation, 
persistence 
Explainable 
non-random 
Yes Yes - Can be used to account 
for real-world adherence 
levels  
- RPSFTM only estimates ǲǳǲ-ǳ
making it applicable to 
adjuǲǳ 
type of adherence only. 
RPSFTMs Yes Initiation Non-random Yes Yes 
PKPD Yes Initiation, 
implementation, 
persistence 
Explainable 
non-random 
Yes Yes - The estimand is 
marginalised to the 
entire population. 
- Can estimate 
effectiveness given 
different adherence 
patterns. 
HTA=Health Technology Assessment; CACE=Complier Average Causal Effect; ITT=Intention-to-Treat; PP=Per-Protcol; 
AT=As Treated; CPH=Cox Proportional Hazards; PLE=Partial Likelihood Estimator; MCC=Markov Compliance Class; 
Wtd PP= Weighted Per-Protocol; C-PROPHET= Complier PROPortional Hazards Effect of Treatment; IV=Instrumental 
Variable; MSMs=Marginal Structural Models; SNFTMs=Structural Nested Failiure Time Models; RPSFTMs= Rank-
Preserving Stuctural FAiliure Time Models; PKPD=Pharmacokinetics and Pharmacodynamics. 
* In the HTA context, the estimand of interest includes the entire study population and this should be identifiable at 
baseline for resource allocation decision making.  
Ș This collumn specifies the type of non-adherence that each adjustment method is capable of dealing with in terms 
of random (non-selective) non-adherence, explainable non-random (selective) non-adherence (i.e. non-adherence 
explainable by observed covariates),  or no-random (selective) non-adherence.  ș In the HTA context, methods for adjusting trial data for non-adherence needs to be capable of re-estimating 
treatment effectiveness for any given level of adherence (e.g. real-world adherence levels). 
 
 
FIGURE LEGENDS  
Figure 1. PRISMA Flow Diagram. Numbers in red represent records from the 2nd iteration of 
searches. The dashed lines show that citation searches and reference list checking were done 
for pearls identified from databases searching. Papers excluded for ǲcomparison of 
known methodsǳ are included in the citation search and reference checking as these were 
considered relevant for this purpose.  
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FIGURES 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
(n =  1520 + 1757) 
Duplicates removed  
(n = 373 + 764) 
Records screened  
(n =  1156 + 993) 
Records excluded  
(n = 1079 + 960) 
By title (n=1048 + 917) 
By abstract (n=31 + 43) 
Records via citation searches 
and references lists  
(n = 895 + 291) 
Records excluded  
(n = 870 + 281) 
By title (n=848 + 271) 
By abstract (n=22 + 10) 
Additional records identified 
through other sources  
(n =  9) 
Full-text articles excluded, with reasons 
(n= 70 + 32): 
 Continuous outcomes (n=17 + 10) 
 Binary outcomes (n=16 + 5) 
 Categorical outcomes (n=5 + 1) 
 No patient outcome (n=7 + 5) 
 Pharmacokinetics and 
Pharmacodynamics only (n= 9 + 1) 
 Economic evaluations (n= 9 + 2) 
 Application of known method 
without extension (n=9 + 8) 
 Not a methodological paper (n=1 +2) 
 Not met definition of non-adherence 
(n= 3) 
 Assessed associations (n= 1) 
 Theoretical paper (n=1) 
 Comparisons of known methods 
(n=6 + 2) 
Full-text articles assessed 
for eligibility  
(n = 77 + 33) 
Papers included in qualitative synthesis  
(n = 20) 
Full-text articles assessed 
for eligibility  
(n =  25 + 10) 
Full-text articles excluded, with 
reasons (n= 19 + 9): 
 Continuous outcomes (n= 8 + 1) 
 Binary outcomes (n= 9 + 1) 
 Categorical outcomes (n= 2) 
 No patient outcome (n=3 + 1) 
  Pharmacokinetics and 
Pharmacodynamics only (n= 3) 
 Economic evaluation (n=1) 
 Application of known method 
without extension (n=7 + 3) 
 Not a methodological paper (n=3) 
 Not peer-reviewed (n=2 +1) 
 Not met definition of non-
adherence (n=2) 
 Assessed associations (n= 1) 
 Theoretical paper (n=1) 
 Comparisons of known methods 
(n=3 +1) 
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Papers included  
(n = 7+ 1) 
Papers suggested by experts  
(n = 4) 
Papers included  
(n = 6 + 2) 
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APPENDICES 
Appendix A: Search terms, strategies and results  
A1: Search terms 
Patient adherence terms include compliance, adherence, pharmacoadherence, persistence, 
persistency, concordance, initiation, implementation, noncompliance, nonadherence, 
nonpersistence, discontinuation, pharmionics, therapeutic alliance, patient irregularity or 
treatment refusal. MeSH headings for methods include ǲǡǳǲǡǳǲǡǳǲǡǳǲǡǳǲǳǲǳǲǳ. 
A2: First iteration searches and results 
MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE(R) Daily, 
MEDLINE and Versions(R): Ovid 1946 to February 9 2018 
 
# Terms Results 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
120596 
2 *Models, Structural/ 2122 
3 *models, statistical/ 28208 
4 *models, economic/ or *models, econometric/ 4387 
5 1 and (2 or 3 or 4) 245 
 
MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE(R) Daily, 
MEDLINE and Versions(R): Ovid 1946 to March 28 2018 Ȃ ǲǡǳ
heading.  
 
3rd April 2018 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
121991 
2 *Models, Structural/ 2128 
3 *Models, Statistical/ 28482 
4 *models, economic/ or *models, econometric/ 4416 
5 *Models, Biological/ 97476 
6 1 and (2 or 3 or 4) 249 
7 1 and 5 625 
8 limit 7 to humans 324 
9 8 not 6 316 
 
 
Embase: Ovid 1974 to 2018 March 30 
3rd April 2018 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
159985 
30 
 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
2 *structural model/ 153 
3 *statistical model/ 21073 
4 *economic model/ 491 
5 *biological model/ 56706 
6 1 and (2 or 3 or 4) 143 
7 1 and 5 381 
8 limit 7 to human 156 
9 6 or 8 298 
 
 
 
Cochrane Library: Wiley 
3rd April 2018 
 
#1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal):ti  (Word variations have been searched) 
12301 
#2 MeSH descriptor: [Models, Structural] this term only 25 
#3 MeSH descriptor: [Models, Statistical] this term only 1577 
#4 MeSH descriptor: [Models, Economic] this term only 1578 
#5 MeSH descriptor: [Models, Econometric] this term only 470 
#6 MeSH descriptor: [Models, Biological] this term only 2370 
#7 #1 and (#2 or #3 or #4 or #5)  52 
#8 #1 and #6  16 
#9 #7 or #8  67 
 
Econlit: Ovid 1886 to May 3, 2018 
8th May 2018 
 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
8632 
2 model*.ti. 90932 
3 (structural or statistical or economic or econometric or biological).ti. 114247 
4 1 and 2 and 3 31 
 
Web of Science: Clarivate Analytics 
8th May 2018 
# 1 TITLE: ((compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation or noncompliance 
or nonadherence or nonpersistence or discontinuation or pharmionics or 
therapeutic alliance or patient irregularity or treatment refusal))  
256,870  
# 2 TITLE: (model*)  1,892,481  
# 3 TITLE: ((structural or statistical or economic or econometric or biological))  706,793  
# 4 #3 AND #2 AND #1  240  
 
 
Scopus: Elsevier 
8th May 2018 
#1 ( TITLE ( ( compliance  OR  adherence  OR  pharmacoadherence  OR  
persistence  OR  persistency  OR  concordance  OR  initiation  OR  
321,353 
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implementation  OR  noncompliance ) )  OR  TITLE ( ( nonadherence  OR  
nonpersistence  OR  discontinuation  OR  pharmionics  OR  therapeutic  AND 
alliance  OR  patient  AND irregularity  OR  treatment  AND refusal ) ) )   
#2 TITLE ( model* )  2,338,498 
#3 TITLE ( ( structural  OR  statistical  OR  economic  OR  econometric  OR  biologi
cal ) )  
905,167 
#4 ( ( TITLE ( ( compliance  OR  adherence  OR  pharmacoadherence  OR  
persistence  OR  persistency  OR  concordance  OR  initiation  OR  
implementation  OR  noncompliance ) )  OR  TITLE ( ( nonadherence  OR  
nonpersistence  OR  discontinuation  OR  pharmionics  OR  therapeutic  AND 
alliance  OR  patient  AND irregularity  OR  treatment  AND refusal ) ) ) )  AND  
( TITLE ( model* ) )  AND  ( TITLE ( ( structural  OR  statistical  OR  economic  
OR  econometric  OR  biological ) ) )   
323 
 
A3: Second iteration searches and results 
 
MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE(R) Daily, 
MEDLINE and Versions(R): Ovid 1946 to May 16, 2018 
22nd May 2018 
# Terms Results 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
123742 
2 *Models, Structural/ 2129 
3 *Models, Statistical/ 28851 
4 *models, economic/ or *models, econometric/ 4476 
5 *Models, Biological/ 98419 
6 1 and (2 or 3 or 4) 250 
7 1 and 5 634 
8 limit 7 to humans 329 
9 8 not 6 321 
10 *Survival Analysis/ 2666 
11 *Proportional Hazards Models/ 1811 
12 *Linear Models/ 2498 
13 *Logistic Models/ 1675 
14 Biometry/mt [Methods] 4244 
15 Randomized Controlled Trials as Topic/sn [Statistics & Numerical Data] 4789 
16 Cost-Benefit Analysis/sn [Statistics & Numerical Data] 981 
17 Economics, Pharmaceutical/sn [Statistics & Numerical Data] 144 
18 or/10-17 17625 
19 pharmacometric*.tw. 388 
20 causal inference.tw. 1455 
21 proportional hazards.ti. 411 
22 structural model*.ti. 1624 
23 proportional hazards model*.ab. 20752 
24 structural nested model*.ab. 27 
25 marginal structural model*.ab. 518 
26 structural proportional hazards.ab. 3 
27 structural accelerated failure.ab. 7 
28 compliance class model*.ab. 2 
29 preserving structural failure.ab. 31 
30 rank preserving structural.ab. 31 
31 accelerated failure time.ab. 479 
32 
 
32 or/19-31 25187 
33 18 or 32 41976 
34 1 and 33 616 
35 limit 34 to humans 523 
36 35 not 9 520 
 
Embase: Ovid 1974 to 2018 May 21 
22nd May 2018 
1 (compliance or adherence or pharmacoadherence or persistence or persistency or 
concordance or initiation or implementation or noncompliance or nonadherence or 
nonpersistence or discontinuation or pharmionics or therapeutic alliance or patient 
irregularity or treatment refusal).ti. 
162336 
2 *structural model/ 160 
3 *statistical model/ 21307 
4 *economic model/ 506 
5 *biological model/ 57036 
6 1 and (2 or 3 or 4) 146 
7 1 and 5 385 
8 limit 7 to human 157 
9 6 or 8 302 
10 *survival analysis/ 645 
11 *proportional hazards model/ 1385 
12 10 or 11 2017 
13 pharmacometric*.tw. 568 
14 causal inference.tw. 1544 
15 proportional hazards.ti. 418 
16 structural model*.ti. 1691 
17 proportional hazards model*.ab. 32565 
18 structural nested model*.ab. 26 
19 marginal structural model*.ab. 681 
20 structural proportional hazards.ab. 3 
21 structural accelerated failure.ab. 9 
22 compliance class model*.ab. 2 
23 preserving structural failure.ab. 98 
24 rank preserving structural.ab. 98 
25 accelerated failure time.ab. 552 
26 or/13-25 37594 
27 1 and (12 or 26) 702 
28 27 not 9 691 
 
Web of Science: Clarivate Analytics 
22nd May 2018 
 
# 1 TITLE: ((compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation or noncompliance or 
nonadherence or nonpersistence or discontinuation or pharmionics or therapeutic 
alliance or patient irregularity or treatment refusal))  
257,485 
# 2 TITLE: (model*)  1,896,217 
# 3 TITLE: ((structural or statistical or economic or econometric or biological))  708,343 
# 4 #3 AND #2 AND #1  240 
# 5 TI=("survival analysis")  3,080 
# 6 TI=("proportional hazards model*")  513 
# 7 TI=("linear model*")  6,683 
# 8 TI=("logistic model*")  789 
33 
 
# 9 TOPIC: (pharmacometric*)  464 
# 10 TS=("causal inference")  3,246 
# 11 TI=("proportional hazards")  823 
# 12 TI=("structural model*")  4,117 
# 13 TI=("proportional hazards model*")  513 
# 14 TOPIC: ("proportional hazards model*")  20,669 
# 15 TOPIC: ("structural nested model*")  43 
# 16 ǣȋǲȗǳȌ 1,192 
# 17 ǣȋǲǳȌ 3 
# 18 TOPIC: ("structural accelerated failure")  9 
# 19 TOPIC: ("compliance class model*")  4 
# 20 TOPIC: ("preserving structural failure")  37 
# 21 TOPIC: ("rank preserving structural")  38 
# 22 TOPIC: ("accelerated failure time")  849 
# 23 #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR 
#12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5  
40,195 
# 24 #23 AND #1  575 
# 25 #24 not #4  519 
 
MathSciNet: American Mathematical Society 
23rd May 2018 
27 records 
 
1.  "Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation )" 
7806 Compliance 
in title 
2.  "Title=(noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics)" 
91 
3.  'Title=("therapeutic alliance" or "patient irregularity" or "treatment 
refusal")' 
0 
4.  "Title=(model*)" 21005 Model in 
title 5.  "Title=(structural or statistical or economic or econometric or biological)" 36577 
6.  ǲ ?ȋ ȗ
model* or logistic model*)" 
507 Second 
iteration 
model 
terms 
7.  "Review Text=(pharmacometricȗǲǲȌ ? 439 
8.  "Review Text=(proportional hazards or structural model* or proportional 
hazards model* or structural nested model*)" 
22 
9.  'Review Text=(marginal structural model* or structural proportional 
hazards or structural accelerated failure or compliance class model*)' 
0 
10.  "Review Text=(preserving structural failure or rank preserving structural 
or accelerated failure time)" 
5 
11.  "Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation ) AND 
Title=(model*) AND Title=(structural or statistical or economic or 
econometric or biological)" 
16 1st search 
12.  "Title=( noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics) AND Title=(model*) AND 
Title=(structural or statistical or economic or econometric or biological)" 
3 
13.  Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation ) AND Review 
Text=(survival analysis or proportional hazards model* or linear model* 
or logistic model*)" ' 
1 2nd search 
(a) 
34 
 
14.  'Title=(noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics) AND Review Text=(survival analysis or 
proportional hazards model* or linear model* or logistic model*)' 
0 
15.  "Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation ) AND Review 
Text=(pharmacometricȗǲǲȌ ? 3 2nd search (b) 
16.  'Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation ) AND Review 
Text=(proportional hazards or structural model* or proportional hazards 
model* or structural nested model*)' 
0 
17.  'Title=(compliance or adherence or pharmacoadherence or persistence or 
persistency or concordance or initiation or implementation ) AND Review 
Text=(preserving structural failure or rank preserving structural or 
accelerated failure time)' 
0 
18.  "Title=(noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics) AND Review Text=(pharmacometric* or ǲǲȌ ? 3 
19.  'Title=(noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics) AND Review Text=(proportional hazards 
or structural model* or proportional hazards model* or structural nested 
model*)' 
0 
20.  "Title=(noncompliance or nonadherence or nonpersistence or 
discontinuation or pharmionics) AND Review Text=(preserving structural 
failure or rank preserving structural or accelerated failure time)" 
1 
21.  or/11-20 27  
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Appendix B: Supplementary Tables  
Table S1 Inclusion and Exclusion Criteria Applied for Selection of Selection of Papers Included 
in the Review 
Inclusion criteria Exclusion criteria 
Peer-reviewed methodological papers which 
describe the method(s) in detail such that they 
can be applied without the need for further 
assumptions;* 
Non-peer reviewed reports, books or book 
chapters, theses, or other grey literature; 
Methods explicitly applied to adjust for non-
adherence in estimating treatment-effects for 
survival-time outcomes and/or cost-
effectiveness; 
Papers which merely apply previously developed 
method(s) without any additional extension to the 
original method(s)+; 
Papers published from databases inception to 
date; and 
Methods which are not explicitly applied to adjust 
for non-adherence to treatments 
Papers published in the English language. Methods based on aggregated data such as meta-
analysis; or 
 Theoretical papers with no application of the 
method. 
 * This criterion is not objective and required a judgement on my part informed by expert advice 
+ This implied that the first paper proposing the method was included and any paper published afterwards with the 
application of the method without any methodological extension was excluded.  
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Table S2 Data Extraction Form 
Basic information Methodological origin 
Paper 
ID# 
Author(s) Year  of 
publication 
Journal Method Method 
acronym 
Methods 
Group 
 
Type of 
methodological 
contribution  
(original/extension) 
Was the method 
originally 
developed to 
adjust for non-
adherence? 
If not, what 
was the 
original 
context and 
how the 
method was 
adapted? 
Does the method 
represent an 
extension to 
another method 
adjusting for 
non-adherence? 
           
 
Table S2 Data Extraction Form (continued) 
Theoretical suitability Application 
How 
does 
the 
method 
work? 
What are the 
key 
assumptions? 
What are 
the 
potential 
biases?  
Why might 
the method 
not be 
appropriate? 
 What are the 
advantages 
and 
disadvantages 
associated 
with the 
method? 
What are 
the 
similarities 
and 
differences 
of the 
method 
compared 
to other 
methods 
identified? 
Has the 
method been 
applied to 
adjust for 
non-
adherence in 
a case/ 
simulation 
study?  
What 
disease/condition 
applied in the 
case/simulation 
study? 
What are 
intervention(s) 
assessed in the 
case/simulation 
study?  
Outcome(s) 
assessed 
What were the 
results 
compared to 
traditional 
approaches 
(ITT/PPT/AT)? 
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Table S3 Appraisal Framework 
Domain Issues considered  
Origin of the method Was the method originally developed to adjust for non-adherence? 
If not, what was the original context and how the method was adapted? 
Does the method represent an extension to another method adjusting for 
non-adherence? 
Theoretical suitability How does the method work? 
What are the key assumptions? 
What are the potential biases? 
Why might the method not be appropriate? 
What are the advantages and disadvantages associated with the method? 
What are the similarities and differences of the method compared to other 
methods identified? 
Application Has the method been applied to adjust for non-adherence in a case 
study/simulation study? 
What disease/condition is applied in the case/simulation study? 
What is/are the intervention(s) assessed in the case/simulation study? 
What were the results compared to simple methods (ITT/PP/AT), if 
compared? 
38 
 
Table S4 Characteristics of Papers Included in the Review (n=20) 
Characteristic No. (%) 
Year 
2014-2018 6(30) 
2009-2013 1(5) 
2004-2008 3(15) 
1999-2003 7(35) 
Before 1999 3(15) 
Journal 
Statistics in Medicine 6(30) 
Biometrics 5(25) 
Journal of the Royal Statistical Society 3(15) 
Journal of the American Statistical Association 2(10) 
Clinical Pharmacology & Therapeutics 1(5) 
Communication in Statistics - Theory and Methods 1(5) 
Epidemiology 1(5) 
Value in Health 1(5) 
Type of study to which the method was applied 
Simulation study 3(15) 
Case study 6(30) 
Both simulation study and case study 11(55) 
Disease area 
Breast cancer 5(25) 
AIDS 3(15) 
Depression 2(10) 
Lung cancer 2(10) 
Leukaemia  2(10) 
Colorectal cancer 1(5) 
Atrial fibrillation  1(5) 
Gout 1(5) 
Vitamin A deficiency  1(5) 
Hypertension 1(5) 
Hypothetical condition 1(5) 
 
 
